Internal mammary lymph node (IMLN) metastasis is one of the important prognostic indicators in breast cancer. However, the management for IMLN metastasis is not established. The dissection for IMLN metastasis is not recommended in the National Comprehensive Cancer Network guidelines version3. 2015. Furthermore, radiotherapy including IMLN region and biopsy have attendant risks and hence should be performed with caution. Here, we describe our experience of multidisciplinary treatment for locally advanced breast cancer with IMLN metastasis in an elderly patient. Core-needle biopsy of the breast tumor histologically diagnosed the tumor as estrogen receptor positive, progesterone receptor positive, human epidermal growth factor receptor-2 negative, and high Ki-67 labeling index. IMLN swelling was detected by ultrasonography and breast cancer metastasis was diagnosed by fine-needle aspiration cytology. The patient underwent mastectomy and axillary lymph node dissection, followed by postmastectomy radiation therapy. Systemic therapy using tegafur plus uracil (UFT®; Taiho Pharmaceutical Co., Ltd, Tokyo, Japan) and letrozole was beneficial treatment for disease control.
Introduction
Lymphatic drainage of the breast is an important process of breast cancer metastasis. Intramammary lymphatics flow toward axillary and/or internal mammary lymph nodes (IMLN). Involvement of IMLN is associated with poor prognosis and has been reported in 11.1-23.5% of who underwent internal mammary sentinel lymph node biopsy [1] [2] [3] . However, internal mammary sentinel lymph node biopsy for accurate staging or IMLN dissection with IMLN metastasis is controversial [4] [5] [6] [7] . The surgical procedure for IMLN sampling carries the risk of pneumothorax or bleeding caused by inadvertent injury to the internal thoracic vessels. Radiation therapy is reported to reduce the number of local recurrences but may cause adverse effects such as radiation dermatitis, pneumonitis, or cardiac disorders [6, 8] . There are no clear recommendations about IMLN metastasis. According to the National Comprehensive Cancer guidelines version 3. 2015, the dissection for IMLN metastasis has much more disadvantages than merits. At least, systemic or local management without resection of metastatic IMLN might benefit patient prognosis.
On the other hand, safety is not always guaranteed for chemotherapy prescribed to elderly people aged over 80 with locally advanced breast cancer.
Herein, an elderly case with IMLN metastatic breast cancer who underwent multidisciplinary therapy is presented the characteristics of breast cancer with IMLN metastasis were reviewed in our institute. This report focus on the therapy of elderly breast cancer patient with IMLN metastatic, locally advanced disease.
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Case report
An 82-year-old woman presented to the outpatient clinic of the Department of Breast Surgery in Shiga General Hospital (Moriyama, Shiga, Japan) with a history of a lump in the right breast for a month. On physical examination, she had a mass measuring 3.5 cm without skin invasion in the upper medial region in her right breast.
Ultrasonography, computed tomography (CT), and breast magnetic resonance imaging (MRI) showed IMLN swelling in right lateral side of her sternum (Fig. 1a) . Core-needle biopsy of the right tumor diagnosed the tumor was high histological grade invasive ductal carcinoma with IMLN metastasis, as estrogen receptor (ER) positive (20%), progesterone receptor (PgR) positive (10%), human epidermal growth factor receptor 2 (HER2) negative (score 1+), and Ki-67 labeling index 50% histologically (Fig. 2) .
Fine-needle aspiration of IMLN revealed metastasis from breast tumor. Radiological study classified she was in cT2N2bM0, stage IIIA disease (UICC-TNM classification 8th edition). Bone scintigraphy using 99m Tc-Methylene diphosphonate (555 MBq) showed there was no evidence of bone metastasis.
Disadvantage of intravenous chemotherapy was concerned due to the age of the patient in stratifying the treatment. Thus, preoperative chemotherapy was not administered; she underwent right mastectomy and axillary lymph node dissection. A metastatic IMLN was not resected. The final histological analysis diagnosed she was in pt2n2b(1/24, and non-removed IMLN)M0, stage IIIA disease.
The patient's performance status was worth treating intensively by the evaluation based on comprehensive geriatric assessment [9] . The patient has no serious comorbidities contribute to overall survival other than breast cancer, so the long-term survival was expected if breast (Fig. 1b) . After PMRT, tegafur plus uracil (UFT®; Taiho Pharmaceutical, Co., Ltd, Tokyo, Japan) 600 mg a day with letrozole 2.5 mg a day were administered as systemic therapy. UFT® was reduced to 400 mg due to grade 2 neutropenia and fatigue according to Common Terminology Criteria of Adverse Event (CTCAE) version 4.0. A year after surgery, CT scan described no evidence of IMLN enlargement or other new metastatic regions radiologically (Fig. 1c) . To date, she has a good quality of life and has demonstrated stable disease for 18 months.
The medical records of 626 operable breast cancer patients were retrospectively reviewed. Between 2007 and 2017, all the patients who underwent breast surgery at Shiga General Hospital were investigated and χ 2 tests were used to analyze qualitative data. Overall survival (OS) was defined as the period from the date of diagnosis to the date of the last follow-up or death from any cause, and disease-free survival (DFS) was defined as the period from the date of diagnosis to occurrence of any event, such as disease progression, relapse, recurrence or death. Kaplan-Meier estimates were used to calculate OS and DFS using Stat Mate V for Win & Mac Hybrid software (ATMS, Tokyo, Japan). Figure 3 shows Kaplan-Meier plot comparing DFS, OS, and BCSS between the patients with N1-3 lymph node metastasis and IMLN metastasis. Patients who experienced postoperative axillary lymph nodes or IMLN metastasis were included in this verification. Because most of patients who underwent local recurrence received insufficient local control, as omission of PMRT for patients with skin invasion or lymph node metastases. As shown in Table 2 , even patients with N1-2 disease did not receive PMRT. Primary local control was considered to contribute to DFS or BCSS. Compared with patients with axillary lymph node metastasis (N1-3), those with IMLN metastasis had no statistically DFS disease-free survival, OS overall survival, BCSS breast cancer-specific survival, IMLN internal mammary lymph node, HR hazard ratio, CI confidence interval significant differences in OS, BCSS (Fig. 3a-c) ; however, the hazard ratios in DFS, OS, and BCSS were worse. Table 1 shows the characteristics of 5 patients with IMLN metastasis at diagnosis, and Table 2 shows those of 7 patients with IMLN recurrence after primary therapy among 626 patients. Primary breast cancer with IMLN metastasis tended to be locally advanced, located in the medial side of the breast, and has a luminal-like phenotype. Four patients, except 1 who had stage IV disease, received irradiation. No patients experienced relapse of IMLN metastasis, and 1 patient died from sepsis from a wound infection 33 months after surgery (Table 1) .
Seven patients experienced IMLN recurrence after primary therapy, although they had no IMLN metastasis at diagnosis (Table 2) . They also tended to have luminal-like tumors. However, the tumors primarily included those with a small diameter and those located in the lateral side of the breast. Five of them (71.4%) were non-irradiated patients after primary surgery. Two patients died within 2 years after IMLN recurrence with visceral metastases (Table 1) .
Discussion
Management of IMLN metastasis is controversial. Surgical resection of metastatic site is harmful more than benefit [4, 6] . Although PMRT including supraclavicular and IMLN region might be effective for local control, it causes unavoidable radiation to healthy tissues and organs [6, 8] . And systemic therapy is another option for disease control. The resected breast tumor was diagnosed as high histological grade, ER positive (20%), PgR positive (10%), HER2 negative (score 1+), and 50% of Ki-67 labeling index. For young patients with such locally advanced, high-grade luminal B-like breast cancer, preoperative chemotherapy including anthracycline and taxane will be administered to evaluate the effect of preoperative chemotherapy [10] . Intensive systemic therapy also is usually performed after surgery since IMLN dissection is not recommended [1] [2] [3] [4] [5] [6] [7] .
In the meta-analysis, PMRT reduced locoregional recurrence, overall recurrence, and BCSS for patients with one to three positive nodes (N1 stage) [11] . And some reports showed PMRT could improve locoregional recurrence, DFS, OS for patients with even T1-2 and N1 stage breast cancer especially with high-risk disease such as age, lymph node ratio, molecular subtype, and lymphovascular invasion [12, 13] . That is, most patients with lymph node metastasis are considered to have good indications of PMRT. In addition, efficacy of PMRT for patients with IMLN metastasis is also indicated in DFS and BSCC [14] .
For such an elderly patient as in this case, disadvantage of intravenous chemotherapy sometimes causes severe adverse effects. According to the comprehensive geriatric assessment for this patient, the long-term survival was expected if breast cancer control was provided [9] . The prognosis varies considerably depending on many factors in elderly patients. Therapeutic strategy becomes sometimes overtreatment or undertreatment if the risk-benefit balance is misdiagnosed. Radiotherapy for elderly patients is sometimes omitted to avoid adverse events. Fortunately, for this case, PMRT was especially effective in local control without any severe radiation-related events such as pneumonitis or pericarditis.
Although endocrine therapy is relatively harmless therapy, endocrine sensitivity may be low in this case (Fig. 2) .
To maintain her quality of life, UFT® was considered to be a useful option instead of intensive chemotherapy [15, 16] . Previous clinical trials in Japan as NSASBC-01 and CUBC showed UFT® had similar effect on DFS and OS to those with classical CMF, and higher quality of life scores to the patients [15, 16] . She has been stable with no recurrence and continuing adjuvant systemic therapy with good quality of life for 18 months postoperatively. UFT® and letrozole will be administered in 2 years [15, 16] , and 5 years after surgery, respectively, if without IMLN relapse.
As shown in Fig. 3 , patients with IMLN metastasis have higher risk of distant metastasis or mortality compared to those with axillary lymph node metastasis. Aggressive therapy, in this situation, chemotherapy with radiation therapy would be effective to prevent postoperative relapse even though with IMLN metastasis, for the patient with good performance status. Since IMLN metastasis is not a lifethreatening situation, oral chemotherapy such as UFT® is one option to avoid adverse event associated with chemotherapy. Based on the guidelines, chemotherapy should not be used concurrently with endocrine therapy. However, such treatment works effectively and harmlessly in some cases.
The limitation of this study is the small number of patients diagnosed with IMLN metastasis. In Fig. 3 , although IMLN metastatic group tended to show lower DFS and BCSS compared to N1-3 stage group, there was no statistical significance. Several percentages of patients with IMLN metastasis were thought to be included in N1-3 stage group in our study, because sentinel lymph node biopsy of IMLN was not performed in our institution. True IMLN metastatic patients and N1-3 stage group should have been compared. However, from this point of view, the influence of IMLN metastasis on the prognosis of breast cancer patients is enormous and the importance of local control is suggested.
Conclusion
Locally advanced breast cancer with IMLN metastasis is controllable by multidisciplinary treatment without resection. For elderly patients, oral chemotherapy as UFT® is a harmless and beneficial option.
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